Enveric Biosciences, Inc. · NASDAQ:ENVB
Enveric Biosciences — Investor Presentation (January 2026)
17 slides from Enveric Biosciences's investor presentation, January 2026
Slide 1: Corporate Presentation Q1 2026
:ENVB CORPORATE PRESENTATION Q1 2026 Enveric.com
Slide 2: Disclaimer
Disclaimer No Offer or Solicitation This communication is for informational purposes only and is not intended to and does not constitute an offer to sell, or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. It does not constitute a prospectus or prospectu
Slide 3: Next Generation Mental Health
Next Generation TM Mental Health
Slide 4: Significant Global Health Issues: Depression, Anxiety & PTSD
Significant Global Health Issues: Depression, Anxiety & PTSD WIDESPREAD LOW EFFICACY 65 million in the US 40% 1 billion globally Experience a neuropsychiatric First line SSRI treatments work disorder at some time in their lives for less than half of patients Source: (NIMH) (SingleCare) (World Heal
Slide 5: Neuroplastogens: A New Class of Drugs
Neuroplastogens: A New Class of Drugs Prefrontal Cortex Healthy Brain: Neurons in the prefrontal cortex (PFC) regulate emotional behavior via Top-Down control of the amygdala. Neuroplastogens stimulate Neuropsychiatric Illness: Reduced neuroplasticity in the PFC, which restores This modulates the fi
Slide 6: Psychedelic Neuroplastogen Drawbacks
Psychedelic Neuroplastogen Drawbacks: • Current psychedelic neuroplastogens in clinical trials cause hallucinations in the patient • Can require 8 hrs in-clinic treatment with two healthcare providers present, plus pre and post treatment counselling • Often require psychotherapy as part of the treat
Slide 7: EB-003: First-in-Class Dual 5-HT2A partial agonist & 5-HT1B Agonist
:ENVB EB-003: First-in-Class: Dual 5-HT2A partial agonist & 5-HT1B Agonist Non-Hallucinogenic, Orally Available 5-HT2A • partial agonism reported to stimulate neuroplasticity in prefrontal cortex (PFC) • responsible for higher-level cognition, decision-making and social behavior 5-HT1B • agonism reg
Slide 8: Big Pharma Validation of Neuroplastogen Hypothesis
Big Pharma Validation of Neuroplastogen Hypothesis 5-HT2A Receptor Agonists Induce Neuroplasticity Recent deals demonstrate Big Pharma’s appetite for 5-HT2A candidates $1.9B option to license $1.2B acquisition of bretisilocin $60M+ acquisition :ENVB
Slide 9: Commercially Proven 5-HT1B/1D Receptor Target
Commercially Proven 5-HT1B/1D Receptor Target 5-HT1B/1D: Proven safe and effective for migraine in millions of patients by Triptan class of drugs • Simatriptan ⚬ (Imitrex) • Rizatriptan ⚬ (Maxalt) Well defined safety and efficacy profile: • Zolmitriptan >100M patients treated worldwide ⚬ (Zomig) 5-H
Slide 10: EB-003: A New Treatment Standard
EB-003: A New Treatment Standard Approved Psychedelic Targeted Benefits* Antidepressants Neuroplastogens For EB-003 Immediate efficacy Low side effects Treatment in-clinic not required Large patient population Induces neuroplasticity in brain * To be proven in human clinical trials :ENVB
Slide 11: EB-003 Development
EB-003 Development Target Characteristics ⚬ Differentiated mechanism: Dual engagement of 5-HT2A and 5-HT1B receptors ⚬ Large addressable market: Multiple high-burden psychiatric conditions with limited effective treatments ⚬ Compelling preclinical profile: Fast-acting, durable, and non-hallucinogeni
Slide 12: EVM401: Lead Discovery Underway
EVM401: Lead Discovery Underway Overview • Novel phenylalkylamines and indolethylamines • Anticipated to interact with key brain receptors associated with mental health disorders and addiction. Potential Applications: • Early analysis suggests EVM401 compounds could target: • Substance use disorders
Slide 13: Market Potential: Redefining the Treatment Landscape for Mental Health Disorders
Market Potential: Redefining the Treatment Landscape for Mental Health Disorders Current Approved Predicted Neuroplastogen Antidepressant Market: EB-003: A Breakthrough Market: Neuroplastogen $20 Billion $35.4 Billion Neuroplastogen drug market anticipated by 2030 Leading Neuroplastogen Source: Cohe
Slide 14: Product Pipeline
Product Pipeline Stage Partner / Licensee Milestone Payments Available for Partnering Partner EB-003 & EVM301 Series Neuroplastogens Preclinical EVM401 Series Neuroplastogens Discovery Out-Licensed Licensee EB-002 & EVM201 Series Psilocin Prodrugs Preclinical MycoMedica Life Sciences $62 Million Top
Slide 15: Management
Management Management Team Board of Directors Scientific Advisors Joseph Tucker, Ph.D. Michael D. Webb Maurizio Fava, M.D. Chief Executive Officer Board Chair Scientific Advisor & Director George Kegler Stephen M. Stahl, M.D. Director, Chair of the Audit Committee Scientific Advisor Kevin Coveney, C
Slide 16: Potential First-in-Class Entrant to Large Mental Health Market
Potential First-in-Class Entrant to Large Mental Health Market EB-003: Novel Mechanism Drug Candidate • Anticipate filing IND in Q3 of 2026 and Phase I start in Q4 2026 New Drug Class Market Opportunity • $30B+ market and expected to grow • Existing treatments only reach half the patients, carry sig
Slide 17: Enveric Biosciences
Nasdag :ENVB ENVERIC ” tener earn Mental Health™ BIOS CIEN CES Enveric.com
Enveric Biosciences — Investor Presentation (January 2026) on 6ix